The Studies
Diabetes, obesity, fatty liver disease, and atherosclerosis are among the most common, costly, and preventable of all health problems, and mainly due to dysregulation of lipid, glucose or energy metabolism. Metabolic dysregulation may cause a number of other chronic diseases and conditions. The researchers also aim to build a collaborative internationally-recognized Center of Excellence for fundamental and translational research in diabetes, obesity and metabolism.
The Statistics
30M+
More than 30 million people in the U.S. have diabetes.
#1
By 2030, non-alcoholic steatohepatitis, will be the #1 reason for liver transplants in the U.S.
39.8%
In 2015-16, 39.8% of adults in the U.S. were affected by obesity.
The Successes
- Uncovered novel pathogenic mechanisms of NAFLD and atherosclerosis
- Identified novel targets for treatment of NAFLD, atherosclerosis, and obesity
- Identified novel mechanisms of bile acid regulation
- Discovered novel roles that non-lipid factors play in vessel blockage
- Dr. Chiang is a recipient of a prestigious Merit Award from NIDDK
The Scientists
Researchers within this area have expertise in studying bile acid, glucose, lipid and lipoprotein metabolism.
The Stories
-
Read the StoryA disease with a not-so-familiar name that often leads to deadly consequences: That’s one way to describe nonalcoholic fatty liver […]
-
Read the StoryTwo medicine students from Northeast Ohio Medical University participated in the 2018 National Institute of Diabetes and Digestive and Kidney […]
-
Read the StoryA symposium held in Santa Fe, New Mexico, was the destination recently for two Northeast Ohio Medical School students who […]
CONTACT
Yanqiao Zhang, M.D.
Director, Diabetes, Obesity & Metabolism Research Focus Area
Phone: 330.325.6693
Email: yzhang@neomed.edu
Diabetes, Obesity & Metabolism Research
#NEOMEDAlumni Dr. Raymond Onders performed the emergency appendectomy on @Browns tight end Austin Hooper. https://t.co/aIavTq6er0
1991 #NEOMEDAlumni and former special assistant to the U.S. president for biodefense @rvenkayya will join the VITAL… https://t.co/j8rhZe8OeS
